Peptide Research Library

CJC-1295 (No DAC)

Main evidence: Community reports. Updated 2026-10-30.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

At a glance, this pack reports a community product description and the Australian regulator's unapproved-product context; it is information only.

Safety and cautions

The cited product information is community material and has not been validated in humans. The official TGA source states that unapproved peptide products have not been evaluated by the TGA for safety, quality or effectiveness.

Australian legal status

Australian legal context checked on 2026-10-30: the official TGA identifies CJC-1295 as an example of an unapproved peptide product. The TGA states that unapproved peptide products are not included in the Australian Register of Therapeutic Goods and that Commonwealth and state or territory requirements can apply to importation, compounding, supply and advertising.

What the sources say

• What it is — CJC-1295 (No DAC) is described by the cited community source as a synthetic analogue of growth hormone-releasing hormone without a Drug Affinity Complex. This is community material and has not been validated in humans. (Community reports; ResearchDosing: CJC-1295 No DAC, 2026-05-16)
• Approval or study status — In Australia, the official TGA identifies CJC-1295 among examples of unapproved peptide products. CJC-1295 (No DAC) is investigational/unapproved in this context, not presented by the TGA as a product with an approved indication. This regulatory-status statement is sourced from the TGA; the pack's product-information evidence level is community and has not been validated in humans. (Community reports; Therapeutic Goods Administration: Understanding responsibilities for unapproved peptide products, 2026-04-13)
• The cited community source describes CJC-1295 No DAC as a synthetic analogue of growth hormone-releasing hormone that is intended to stimulate pituitary growth-hormone production. This is a community report and has not been validated in humans. (Community reports; ResearchDosing: CJC-1295 No DAC, 2026-05-16)
• The community source distinguishes the No DAC formulation as one without a Drug Affinity Complex and describes it as shorter acting than its DAC counterpart. This is community material and has not been validated in humans. (Community reports; ResearchDosing: CJC-1295 No DAC, 2026-05-16)

Sources

1. ResearchDosing: CJC-1295 No DAC (2026-05-16)
2. Therapeutic Goods Administration: Understanding responsibilities for unapproved peptide products (2026-04-13)

Dosing, stacking and protocol details are not published here.